<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191215045743N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-23</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effectiveness of neurofeedback on irritable bowel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of neurofeedback on the severity of gastrointestinal symptoms, depression, anxiety, stress and quality of life in patients with irritable bowel syndrome (IBS)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48433</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants include 45 people who are randomly assigned to three groups.  Our method of randomization will be Random allocation rule that is a simple way of randomization. The randomization unit is the patient who is assigned to one of the groups A, B and C by the law of random allocation. In this way, the code of each person is recorded inside a lottery ball and is randomly removed from the container without any replacement and the created sequence is created. In this process, the person who assigns patients to the groups is not aware of the type of treatment groups. and does not know what intervention the next group is related to, Blinding description: In this study, those who randomly assign participants to treatment groups do not know the nature of the groups. Therapists are also unaware of the type of treatment of other groups. Evaluators are also unaware of the type of groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Irritable Bowel Syndrom.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Neurofeedback:For the intervention group, the neurofeedback method is performed from the unipolar protocol of anxiety at point PZ and for the treatment of depression at point F3. Treatment plan include 20  sessions which is done three times a week. Intervention 2: Intervention group: Placebo (quasi-neurofeedback): for the placebo control group where the Active Electrodes are placed in the middle of the skull at point CZ and the Grand Electrode is attached to the softness of the patient's ear.similar to intervention group,  placebo Treatment plan include 20  sessions which is done three times a week. Intervention 3: Control group: Routine gastrointestinal medications:This group receives only routine gastrointestinal medication according to the opinion of the gastroenterologist. Simultaneous evaluation is performed before and after the intervention of the intervention groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Findings and data including the severity of gastrointestinal symptoms, anxiety, depression, stress and quality of life before and after the intervention can be shared.

When:
Access starts 4 months after the article is published

To whom:
Data and documentation are available to academic researchers and medical staff.

Conditions:
Citing the source and preserving the rights of the researchers in this study

Where to obtain:
Refer to the Vice Chancellor for Research, Isfahan University of Medical Sciences

How to obtain:
The applicant can write a letter to the Vice Chancellor for Research of Isfahan University of Medical Sciences and request to receive the file. With the coordination of the executors, the files will be provided to the applicant

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amrollah Ebrahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Health Psychology, Medicine School, Isfahan University of Medical Sciences, Hezarjirib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 9313</telephone>
        <email>a_ebrahimi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amrollah Ebrahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 5, Niloufar Building, Varpshti Alley, Sharafuddin Alley West Shariati Street, Hakim Nezami Avenue</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8173955174</zip>
        <telephone>+98 31 3625 8818</telephone>
        <email>amrollahebi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having diagnostic criteria for IBS based on Rome III criteria , all three types of IBS included: C, D and  M kind
age between 18 and 45 years
education:  at least second level at middle school degree</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients who refused to participate in study
positive Family history of colon cancer
WBC, parasites and blood in the stool
History of thyroid disorders  and abnormal thyroid test,
Patients with unstable weight loss, anemia and eosinophilia, rectosigmoid and abnormal scoping
Having  diagnostic Criteria of Severe psychiatric  and neurological disorders  based on   psychiatrist diagnosis.
Having bloody stools</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K58</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Irritable bowel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Neurofeedback:For the intervention group, the neurofeedback method is performed from the unipolar protocol of anxiety at point PZ and for the treatment of depression at point F3. Treatment plan include 20  sessions which is done three times a week.</i_keyword>
      <i_keyword>Intervention group: Placebo (quasi-neurofeedback): for the placebo control group where the Active Electrodes are placed in the middle of the skull at point CZ and the Grand Electrode is attached to the softness of the patient's ear.similar to intervention group,  placebo Treatment plan include 20  sessions which is done three times a week.</i_keyword>
      <i_keyword>Control group: Routine gastrointestinal medications:This group receives only routine gastrointestinal medication according to the opinion of the gastroenterologist. Simultaneous evaluation is performed before and after the intervention of the intervention groups.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of gastrointestinal symptoms of irritable bowel syndrome based on IBS Symptom Severity Questionnaire,Symptoms of depression, anxiety and stress based on the score in DASS-42,Quality of life based on score in IBS-QOL-34 questionnaire. Timepoint: Before the intervention, the severity of gastrointestinal symptoms, depression, anxiety, stress and quality of life are measured. The list of alpha and beta waves is saved after each session. At the end of the sessions, the rate of gastrointestinal symptoms, psychological symptoms and quality of life are measured. Method of measurement: IBS-SSS Intensity of Gastrointestinal Symptoms Questionnaire, DASS-42 Questionnaire - Quality of Life Assessment QOL-34. Record brain waves of alpha and beta waves.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-04</approval_date>
        <contact_name>Ethics committee of Isfahan University of medical Sciences</contact_name>
        <contact_address>Hezarjirib,Isfahan University of Medical Sciences ISFAHAN Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
